Article(id=1330183539162722652, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2023.02.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1661961600000, receivedDateStr=2022-09-01, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795070069350, onlineDateStr=2026-11-19, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795070069350, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795070069350, creator=13701087609, updateTime=1795070069350, updator=13701087609, issue=Issue{id=1330183519441105099, tenantId=1146029695717560320, journalId=1319690259887390882, year='2023', volume='54', issue='2', pageStart='165', pageEnd='294', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795070064649, creator='13701087609', updateTime=1795080429540, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330226993464979643, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330226993464979644, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=182, endPage=190, ext={EN=ArticleExt(id=1330183539355660637, articleId=1330183539162722652, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Development of Antineoplastics Targeting Blocking Protein-protein Interactions, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Protein-protein interactions(PPIs) and the protein complexes formed through the interactions are essential for the cells to perform various basic functions. Most important life activities, such as DNA replication and transcription, protein synthesis and transport, cellular signal transduction and regulation of substance metabolism, are maintained through dense PPI networks. Genetic mutations, epigenetic alterations, and changes in the cellular microenvironment can interfere with PPI patterns or directly induce protein binding to form new tumor-specific interactions, leading to the genesis, progression, invasion and metastasis of tumors. In recent years, significant progress has been made in developing antineoplastics targeting PPI, some of which are in clinical trials or have been approved for marketing. There is growing evidence that drugs targeting specific PPI may have higher specificity and efficacy than those that inhibit the activity of proto-oncogene proteins and offer therapeutic opportunities to cure specific cancers. This paper systematically reviews the research progress of antineoplastics targeting PPI, and describes the challenges and countermeasures for the research of antineoplastics targeting PPI to provide a reference for their development.

, authors=Xi CHEN, Nan JIANG*, authorsList=Xi CHEN, Nan JIANG, authorCompany=null, correspAuthors=Nan JIANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330183539590541662, articleId=1330183539162722652, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=靶向阻断蛋白-蛋白相互作用的抗肿瘤药研发, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

蛋白-蛋白相互作用(PPI)以及通过相互作用而形成的蛋白复合物是细胞完成各项基本功能的重要基础。大多数重要的生命活动,如DNA的复制与转录、蛋白质的合成与转运、细胞信号转导与物质代谢调节等,都是通过密集的PPI网络维持的。基因突变、表观遗传学改变、细胞微环境变化能够干扰PPI模式或者直接诱导蛋白结合,形成新的、肿瘤特有的相互作用,导致肿瘤的发生、发展、侵袭以及转移。近年来,以PPI为靶点进行的抗肿瘤药研发取得了显著进展,有些药物正处于临床试验阶段或已获得批准上市。越来越多的证据表明,靶向特异性PPI的药物可能比抑制原癌基因蛋白活性的药物具有更高的特异性和疗效,为治愈特定肿瘤提供了治疗机遇。该综述系统总结了靶向PPI的抗肿瘤药研究进展,阐述其研发所面临的挑战及对策,以期为靶向PPI的抗肿瘤药研发提供参考。

, authors=陈曦, 蒋南*, authorsList=陈曦, 蒋南, authorCompany=null, correspAuthors=蒋南, authorNote=

陈曦(1999—),女,硕士研究生,专业方向:计算机辅助药物设计。

, correspAuthorsNote=
蒋南(1979—),女,副教授,从事计算机辅助药物设计和药物合成研究工作。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=79+s6/E/MFl9cm1VK8kHqQ==, magXml=/qb8vTj0ZUIQxSAsPTkrIQ==, pdfUrl=null, pdf=J51ONjFjI1X+zHfGeACeOQ==, pdfFileSize=2256628, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=Rh+ANU6oIi3Ek6GmOETcgA==, mapNumber=null, fund=null)}, authors=[Author(id=1330183541918380388, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183542052598118, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183541918380388, language=EN, stringName=Xi CHEN, firstName=Xi, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Pharmacy, Nanjing Medical University, Nanjing 211166, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183542119706983, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183541918380388, language=CN, stringName=陈曦, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学药学院,江苏 南京 211166, bio={"content":"

陈曦(1999—),女,硕士研究生,专业方向:计算机辅助药物设计。

"}, bioImg=null, bioContent=

陈曦(1999—),女,硕士研究生,专业方向:计算机辅助药物设计。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183541717053792, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, xref=null, ext=[AuthorCompanyExt(id=1330183541817717089, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing Medical University, Nanjing 211166), AuthorCompanyExt(id=1330183541842882914, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学药学院,江苏 南京 211166)])]), Author(id=1330183542191010153, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=jiangnan@njmu.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330183542404919659, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183542191010153, language=EN, stringName=Nan JIANG, firstName=Nan, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=School of Pharmacy, Nanjing Medical University, Nanjing 211166, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183542501388652, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183542191010153, language=CN, stringName=蒋南, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学药学院,江苏 南京 211166, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183541717053792, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, xref=null, ext=[AuthorCompanyExt(id=1330183541817717089, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing Medical University, Nanjing 211166), AuthorCompanyExt(id=1330183541842882914, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学药学院,江苏 南京 211166)])])], keywords=[Keyword(id=1330183542639800685, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=EN, orderNo=1, keyword=protein-protein interaction), Keyword(id=1330183542702715246, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=EN, orderNo=2, keyword=antineoplastics), Keyword(id=1330183542870487408, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=EN, orderNo=3, keyword=small molecule inhibitor), Keyword(id=1330183542937596273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=EN, orderNo=4, keyword=polypeptide inhibitor), Keyword(id=1330183542992122226, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=EN, orderNo=5, keyword=targeting), Keyword(id=1330183543071814003, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=CN, orderNo=1, keyword=蛋白-蛋白相互作用), Keyword(id=1330183543130534260, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=CN, orderNo=2, keyword=抗肿瘤药), Keyword(id=1330183543243780469, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=CN, orderNo=3, keyword=小分子抑制剂), Keyword(id=1330183543298306423, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=CN, orderNo=4, keyword=多肽抑制剂), Keyword(id=1330183543369609592, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, language=CN, orderNo=5, keyword=靶向)], refs=[Reference(id=1330183543549964665, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=IDEKER T, SHARAN R. Protein networks in disease [J]. Genome Res, 2008, 18(4): 644-652., articleTitle=null, refAbstract=null), Reference(id=1330183543671599482, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646-674., articleTitle=null, refAbstract=null), Reference(id=1330183543747096955, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=SIDDIQUI F A, PARKKOLA H, MANOHARAN G B, et al. Medium-throughput detection of Hsp90/Cdc37 protein-protein interaction inhibitors using a split renilla luciferase-based assay [J]. SLAS Discov, 2020, 25(2): 195-206., articleTitle=null, refAbstract=null), Reference(id=1330183543830983036, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG Q Y, WU X X, ZHOU J R, et al. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core[J]. Eur J Med Chem, 2021, 210: 112959., articleTitle=null, refAbstract=null), Reference(id=1330183544053281149, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=ZENG X Y, XIE H, YUAN J, et al. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression [J]. Cancer Biol Ther, 2019, 20(7): 956-966., articleTitle=null, refAbstract=null), Reference(id=1330183545747779966, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG M N, ZHANG L X, HEI R X, et al. CDK inhibitors in cancer therapy, an overview of recent development [J]. Am J Cancer Res, 2021, 11(5): 1913-1935., articleTitle=null, refAbstract=null), Reference(id=1330183545827471743, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=TIWARI S, DWIVEDI U N. Discovering innovative drugs targeting both cancer and cardiovascular disease by shared protein-protein interaction network analyses [J]. OMICS,2019, 23(9): 417-425., articleTitle=null, refAbstract=null), Reference(id=1330183545944912256, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=ROSELL M, FERNÁNDEZ-RECIO J. Hot-spot analysis for drug discovery targeting protein-protein interactions [J]. Expert Opin Drug Discov, 2018, 13(4): 327-338., articleTitle=null, refAbstract=null), Reference(id=1330183546003632513, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=COWMAN S J, FUJA D G, LIU X D, et al. Macrophage HIF-1α is an independent prognostic indicator in kidney cancer [J]. Clin Cancer Res, 2020, 26(18): 4970-4982., articleTitle=null, refAbstract=null), Reference(id=1330183546070741378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=VASSILEV L T, VU B T, GRAVES B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 [J]. Science, 2004, 303(5659): 844-848., articleTitle=null, refAbstract=null), Reference(id=1330183546360148355, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO Y J, YU S H, SUN W, et al. A potent small-molecule inhibitor of the MDM2-p53 interaction(MI-888) achieved complete and durable tumor regression in mice [J]. J Med Chem, 2013, 56(13): 5553-5561., articleTitle=null, refAbstract=null), Reference(id=1330183546490171780, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG S M, SUN W, ZHAO Y J, et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression [J]. Cancer Res,2014, 74(20): 5855-5865., articleTitle=null, refAbstract=null), Reference(id=1330183546574057861, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=KONOPLEVA M, MARTINELLI G, DAVER N, et al. MDM2 inhibition: an important step forward in cancer therapy [J]. Leukemia, 2020, 34(11): 2858-2874., articleTitle=null, refAbstract=null), Reference(id=1330183546641166726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=OLTERSDORF T, ELMORE S W, SHOEMAKER A R, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J]. Nature, 2005, 435(7042): 677-681., articleTitle=null, refAbstract=null), Reference(id=1330183546704081287, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=KARPEL-MASSLER G, ISHIDA C T, ZHANG Y R, et al. Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma [J]. Expert Opin Drug Discov, 2017, 12(10): 1031-1040., articleTitle=null, refAbstract=null), Reference(id=1330183546783773064, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=SOUERS A J, LEVERSON J D, BOGHAERT E R, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets [J]. Nat Med,2013, 19(2): 202-208., articleTitle=null, refAbstract=null), Reference(id=1330183546846687625, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=BERG T, COHEN S B, DESHARNAIS J, et al. Small-molecule antagonists of MYC/MAX dimerization inhibit MYC-induced transformation of chicken embryo fibroblasts[J]. Proc Natl Acad Sci USA, 2002, 99(6): 3830-3835., articleTitle=null, refAbstract=null), Reference(id=1330183546926379402, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=YIN X Y, GIAP C, LAZO J S, et al. Low molecular weight inhibitors of MYC-MAX interaction and function [J]. Oncogene, 2003, 22(40): 6151-6159., articleTitle=null, refAbstract=null), Reference(id=1330183547010265483, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=HART J R, GARNER A L, YU J, et al. Inhibitor of MYC identified in a Krohnke pyridine library [J]. Proc Natl Acad Sci USA, 2014, 111(34): 12556-12561., articleTitle=null, refAbstract=null), Reference(id=1330183547081568652, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=SINGH A, KUMAR A, KUMAR P, et al. A novel inhibitor L755507 efficiently blocks c-MYC-MAX heterodimerization and induces apoptosis in cancer cells [J]. J Biol Chem,2021, 297(1): 100903., articleTitle=null, refAbstract=null), Reference(id=1330183547148677517, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG C, LIU J, XU D D, et al. Gain-of-function mutant p53 in cancer progression and therapy [J]. J Mol Cell Biol,2020, 12(9): 674-687., articleTitle=null, refAbstract=null), Reference(id=1330183547224174990, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU J, ZHANG C, HU W W, et al. Tumor suppressor p53 and its mutants in cancer metabolism [J]. Cancer Lett,2015, 356(2 Pt A): 197-203., articleTitle=null, refAbstract=null), Reference(id=1330183547278700943, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=VOUSDEN K H, LU X. Live or let die: the cell’s response to p53 [J]. Nat Rev Cancer, 2002, 2(8): 594-604., articleTitle=null, refAbstract=null), Reference(id=1330183547375169936, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=DONEHOWER L A, HARVEY M, SLAGLE B L, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours [J]. Nature, 1992, 356(6366): 215-221., articleTitle=null, refAbstract=null), Reference(id=1330183547433890193, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=ZAFAR A, WANG W, LIU G, et al. Targeting the p53-MDM2 pathway for neuroblastoma therapy: rays of hope[J]. Cancer Lett, 2021, 496: 16-29., articleTitle=null, refAbstract=null), Reference(id=1330183547505193362, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=LUO X, O’NEILL K L, HUANG K. The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?[J]. F1000Res, 2020, 9: F1000 Faculty Rev-935., articleTitle=null, refAbstract=null), Reference(id=1330183547589079443, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=EDLICH F. BCL-2 proteins and apoptosis: recent insights and unknowns [J]. Biochem Biophys Res Commun, 2018,500(1): 26-34., articleTitle=null, refAbstract=null), Reference(id=1330183547651994004, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=DUFFY M J, O’GRADY S, TANG M H, et al. MYC as a target for cancer treatment [J]. Cancer Treat Rev, 2021, 94:102154., articleTitle=null, refAbstract=null), Reference(id=1330183547719102869, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=YAMASHITA T, HIGASHI M, MOMOSE S, et al. Decreased MYC-associated factor X(MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma [J]. Sci Rep, 2020, 10(1): 10391., articleTitle=null, refAbstract=null), Reference(id=1330183547823960470, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=LI Q, QUAN L, LYU J K, et al. Discovery of peptide inhibitors targeting human programmed death 1(PD-1) receptor [J]. Oncotarget, 2016, 7(40): 64967-64976., articleTitle=null, refAbstract=null), Reference(id=1330183547907846551, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN T K, LI Q, LIU Z L, et al. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy? [J]. Eur J Med Chem, 2019,161: 378-398., articleTitle=null, refAbstract=null), Reference(id=1330183547979149720, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=PAN C H, YANG H Y, LU Y, et al. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation [J]. Eur J Med Chem,2021, 213: 113170., articleTitle=null, refAbstract=null), Reference(id=1330183548050452889, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=WU D D, GAO Y F, CHEN L X, et al. Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice [J]. Peptides, 2010, 31(5): 850-864., articleTitle=null, refAbstract=null), Reference(id=1330183548125950362, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=GHASEMALI S, FARAJNIA S, BARZEGAR A, et al. Rational design of anti-angiogenic peptides to inhibit VEGF/VEGFR2 interactions for cancer therapeutics [J]. Anticancer Agents Med Chem, 2021, 22(10): 2026-2035., articleTitle=null, refAbstract=null), Reference(id=1330183548205642139, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG H F, SUN Y X, ZHOU X M, et al. CD47/SIRPalpha blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy [J]. J Immunother Cancer, 2020, 8(2): e000905., articleTitle=null, refAbstract=null), Reference(id=1330183548281139612, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=HAZAMA D, YIN Y Z, MURATA Y, et al. Macrocyclic peptide-mediated blockade of the CD47-SIRP alpha interaction as a potential cancer immunotherapy [J]. Cell Chem Biol, 2020, 27(9): 1181-1191., articleTitle=null, refAbstract=null), Reference(id=1330183548344054173, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=YI M, NIU M K, XU L P, et al. Regulation of PD-L1 expression in the tumor microenvironment [J]. J Hematol Oncol, 2021, 14(1): 10., articleTitle=null, refAbstract=null), Reference(id=1330183548457300382, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG J, HU L Q. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: from antibodies to small molecules [J]. Med Res Rev, 2019, 39(1): 265-301., articleTitle=null, refAbstract=null), Reference(id=1330183548637655455, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=MARQUINA G, MANZANO A, CASADO A. Targeted agents in cervical cancer: beyond bevacizumab [J]. Curr Oncol Rep, 2018, 20(5): 40., articleTitle=null, refAbstract=null), Reference(id=1330183550235685280, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=VEILLETTE A, CHEN J. SIRPα-CD47 immune checkpoint blockade in anticancer therapy [J]. Trends Immunol, 2018,39(3): 173-184., articleTitle=null, refAbstract=null), Reference(id=1330183550386680225, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=LOGTENBERG M E W, SCHEEREN F A, SCHUMACHER T N. The CD47-SIRPα immune checkpoint [J]. Immunity,2020, 52(5): 742-752., articleTitle=null, refAbstract=null), Reference(id=1330183550508315042, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=SHIN W H, KUMAZAWA K, IMAI K, et al. Current challenges and opportunities in designing protein-protein interaction targeted drugs [J]. Adv Appl Bioinform Chem,2020, 13: 11-25., articleTitle=null, refAbstract=null), Reference(id=1330183550583812515, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=SCOTT D E, BAYLY A R, ABELL C, et al. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge [J]. Nat Rev Drug Discov,2016, 15(8): 533-550., articleTitle=null, refAbstract=null), Reference(id=1330183550646727076, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=RAJAMANI K, THIRUGNANASAMBANDAN S S, NATESAN C, et al. Squalene deters drivers of RCC disease progression beyond VHL status [J]. Cell Biol Toxicol, 2021,37(4): 611-631., articleTitle=null, refAbstract=null), Reference(id=1330183550730613157, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=XUE X, KANG J B, YANG X, et al. An efficient strategy for digging protein-protein interactions for rational drug design — a case study with HIF-1α/VHL [J]. Eur J Med Chem, 2022, 227: 113871., articleTitle=null, refAbstract=null), Reference(id=1330183550814499238, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=BUCKLEY D L, VAN MOLLE I, GAREISS P C, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction [J]. J Am Chem Soc, 2012, 134(10): 4465-4468., articleTitle=null, refAbstract=null), Reference(id=1330183550889996711, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=PELAY-GIMENO M, GLAS A, KOCH O, et al. Structure-based design of inhibitors of protein-protein interactions:mimicking peptide binding epitopes [J]. Angew Chem Int Ed Engl, 2015, 54(31): 8896-8927., articleTitle=null, refAbstract=null), Reference(id=1330183550965494184, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG Z, LI Z L, JI H T. Direct targeting of β-catenin in the wnt signaling pathway: current progress and perspectives[J]. Med Res Rev, 2021, 41(4): 2109-2129., articleTitle=null, refAbstract=null), Reference(id=1330183551200375209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=VAREKA M, DAHMS B, LANG M, et al. Synthesis of a Bcl9 alpha-helix mimetic for inhibition of PPIs by a combination of electrooxidative phenol coupling and Pd-catalyzed cross coupling [J]. Catalysts, 2020, 10(3): 340., articleTitle=null, refAbstract=null), Reference(id=1330183551338787242, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=SONG J M, MENON A, MITCHELL D C, et al. High-throughput chemical probing of full-length protein-protein interactions [J]. ACS Comb Sci, 2017, 19(12): 763-769., articleTitle=null, refAbstract=null), Reference(id=1330183551397507499, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=FASOLINI M, WU X Q, FLOCCO M, et al. Hot spots in Tcf4 for the interaction with beta-catenin [J]. J Biol Chem,2003, 278(23): 21092-21098., articleTitle=null, refAbstract=null), Reference(id=1330183551544308140, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=BANCET A, RAINGEVAL C, LOMBERGET T, et al. Fragment linking strategies for structure-based drug design[J]. J Med Chem, 2020, 63(20): 11420-11435., articleTitle=null, refAbstract=null), Reference(id=1330183551691108781, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=YAN F, LIU G M, CHEN T T, et al. Structure-based virtual screening and biological evaluation of peptide inhibitors for polo-box domain [J]. Molecules, 2019, 25(1): 107., articleTitle=null, refAbstract=null), Reference(id=1330183551774994862, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN Y, LIU W, CHEN L, et al. Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy [J]. Biomaterials,2021, 275: 120944., articleTitle=null, refAbstract=null), Reference(id=1330183551833715119, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=YAN J, YAO Y, YAN S, et al. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction [J]. Nano Lett, 2020, 20(8): 5844-5852., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330183541717053792, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, xref=null, ext=[AuthorCompanyExt(id=1330183541817717089, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing Medical University, Nanjing 211166), AuthorCompanyExt(id=1330183541842882914, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学药学院,江苏 南京 211166)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.02.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2023.02.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2023.02.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2023.02.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
靶向阻断蛋白-蛋白相互作用的抗肿瘤药研发
陈曦 , 蒋南 *
中国医药工业杂志 | 综述 2023,54(2): 182-190
收起
收藏切换
中国医药工业杂志 |综述 2023 , 54 (2) : 182 -190
靶向阻断蛋白-蛋白相互作用的抗肿瘤药研发
全屏
[Author(id=1330183541918380388, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183542052598118, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183541918380388, language=EN, stringName=Xi CHEN, firstName=Xi, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Pharmacy, Nanjing Medical University, Nanjing 211166, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183542119706983, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183541918380388, language=CN, stringName=陈曦, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学药学院,江苏 南京 211166, bio={"content":"

陈曦(1999—),女,硕士研究生,专业方向:计算机辅助药物设计。

"}, bioImg=null, bioContent=

陈曦(1999—),女,硕士研究生,专业方向:计算机辅助药物设计。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183541717053792, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, xref=null, ext=[AuthorCompanyExt(id=1330183541817717089, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing Medical University, Nanjing 211166), AuthorCompanyExt(id=1330183541842882914, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学药学院,江苏 南京 211166)])]), Author(id=1330183542191010153, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=jiangnan@njmu.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330183542404919659, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183542191010153, language=EN, stringName=Nan JIANG, firstName=Nan, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=School of Pharmacy, Nanjing Medical University, Nanjing 211166, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183542501388652, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, authorId=1330183542191010153, language=CN, stringName=蒋南, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学药学院,江苏 南京 211166, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183541717053792, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, xref=null, ext=[AuthorCompanyExt(id=1330183541817717089, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing Medical University, Nanjing 211166), AuthorCompanyExt(id=1330183541842882914, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183539162722652, companyId=1330183541717053792, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学药学院,江苏 南京 211166)])])]
陈曦, 蒋南*
作者信息
  • 南京医科大学药学院,江苏 南京 211166
通讯作者:
蒋南(1979—),女,副教授,从事计算机辅助药物设计和药物合成研究工作。E-mail:
作者简介:

陈曦(1999—),女,硕士研究生,专业方向:计算机辅助药物设计。

Development of Antineoplastics Targeting Blocking Protein-protein Interactions
Xi CHEN, Nan JIANG*
Affiliations
  • School of Pharmacy, Nanjing Medical University, Nanjing 211166
出版时间: 2023-02-10 doi: 10.16522/j.cnki.cjph.2023.02.003
文章导航
收藏切换

蛋白-蛋白相互作用(PPI)以及通过相互作用而形成的蛋白复合物是细胞完成各项基本功能的重要基础。大多数重要的生命活动,如DNA的复制与转录、蛋白质的合成与转运、细胞信号转导与物质代谢调节等,都是通过密集的PPI网络维持的。基因突变、表观遗传学改变、细胞微环境变化能够干扰PPI模式或者直接诱导蛋白结合,形成新的、肿瘤特有的相互作用,导致肿瘤的发生、发展、侵袭以及转移。近年来,以PPI为靶点进行的抗肿瘤药研发取得了显著进展,有些药物正处于临床试验阶段或已获得批准上市。越来越多的证据表明,靶向特异性PPI的药物可能比抑制原癌基因蛋白活性的药物具有更高的特异性和疗效,为治愈特定肿瘤提供了治疗机遇。该综述系统总结了靶向PPI的抗肿瘤药研究进展,阐述其研发所面临的挑战及对策,以期为靶向PPI的抗肿瘤药研发提供参考。

蛋白-蛋白相互作用  /  抗肿瘤药  /  小分子抑制剂  /  多肽抑制剂  /  靶向

Protein-protein interactions(PPIs) and the protein complexes formed through the interactions are essential for the cells to perform various basic functions. Most important life activities, such as DNA replication and transcription, protein synthesis and transport, cellular signal transduction and regulation of substance metabolism, are maintained through dense PPI networks. Genetic mutations, epigenetic alterations, and changes in the cellular microenvironment can interfere with PPI patterns or directly induce protein binding to form new tumor-specific interactions, leading to the genesis, progression, invasion and metastasis of tumors. In recent years, significant progress has been made in developing antineoplastics targeting PPI, some of which are in clinical trials or have been approved for marketing. There is growing evidence that drugs targeting specific PPI may have higher specificity and efficacy than those that inhibit the activity of proto-oncogene proteins and offer therapeutic opportunities to cure specific cancers. This paper systematically reviews the research progress of antineoplastics targeting PPI, and describes the challenges and countermeasures for the research of antineoplastics targeting PPI to provide a reference for their development.

protein-protein interaction  /  antineoplastics  /  small molecule inhibitor  /  polypeptide inhibitor  /  targeting
陈曦, 蒋南. 靶向阻断蛋白-蛋白相互作用的抗肿瘤药研发. 中国医药工业杂志, 2023 , 54 (2) : 182 -190 . DOI: 10.16522/j.cnki.cjph.2023.02.003
Xi CHEN, Nan JIANG. Development of Antineoplastics Targeting Blocking Protein-protein Interactions[J]. Chinese Journal of Pharmaceuticals, 2023 , 54 (2) : 182 -190 . DOI: 10.16522/j.cnki.cjph.2023.02.003

参考文献 引证文献
排序方式:
[1]
IDEKER T, SHARAN R. Protein networks in disease [J]. Genome Res, 2008, 18(4): 644-652.
[2]
HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646-674.
[3]
SIDDIQUI F A, PARKKOLA H, MANOHARAN G B, et al. Medium-throughput detection of Hsp90/Cdc37 protein-protein interaction inhibitors using a split renilla luciferase-based assay [J]. SLAS Discov, 2020, 25(2): 195-206.
[4]
ZHANG Q Y, WU X X, ZHOU J R, et al. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core[J]. Eur J Med Chem, 2021, 210: 112959.
[5]
ZENG X Y, XIE H, YUAN J, et al. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression [J]. Cancer Biol Ther, 2019, 20(7): 956-966.
[6]
ZHANG M N, ZHANG L X, HEI R X, et al. CDK inhibitors in cancer therapy, an overview of recent development [J]. Am J Cancer Res, 2021, 11(5): 1913-1935.
[7]
TIWARI S, DWIVEDI U N. Discovering innovative drugs targeting both cancer and cardiovascular disease by shared protein-protein interaction network analyses [J]. OMICS,2019, 23(9): 417-425.
[8]
ROSELL M, FERNÁNDEZ-RECIO J. Hot-spot analysis for drug discovery targeting protein-protein interactions [J]. Expert Opin Drug Discov, 2018, 13(4): 327-338.
[9]
COWMAN S J, FUJA D G, LIU X D, et al. Macrophage HIF-1α is an independent prognostic indicator in kidney cancer [J]. Clin Cancer Res, 2020, 26(18): 4970-4982.
[10]
VASSILEV L T, VU B T, GRAVES B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 [J]. Science, 2004, 303(5659): 844-848.
[11]
ZHAO Y J, YU S H, SUN W, et al. A potent small-molecule inhibitor of the MDM2-p53 interaction(MI-888) achieved complete and durable tumor regression in mice [J]. J Med Chem, 2013, 56(13): 5553-5561.
[12]
WANG S M, SUN W, ZHAO Y J, et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression [J]. Cancer Res,2014, 74(20): 5855-5865.
[13]
KONOPLEVA M, MARTINELLI G, DAVER N, et al. MDM2 inhibition: an important step forward in cancer therapy [J]. Leukemia, 2020, 34(11): 2858-2874.
[14]
OLTERSDORF T, ELMORE S W, SHOEMAKER A R, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J]. Nature, 2005, 435(7042): 677-681.
[15]
KARPEL-MASSLER G, ISHIDA C T, ZHANG Y R, et al. Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma [J]. Expert Opin Drug Discov, 2017, 12(10): 1031-1040.
[16]
SOUERS A J, LEVERSON J D, BOGHAERT E R, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets [J]. Nat Med,2013, 19(2): 202-208.
[17]
BERG T, COHEN S B, DESHARNAIS J, et al. Small-molecule antagonists of MYC/MAX dimerization inhibit MYC-induced transformation of chicken embryo fibroblasts[J]. Proc Natl Acad Sci USA, 2002, 99(6): 3830-3835.
[18]
YIN X Y, GIAP C, LAZO J S, et al. Low molecular weight inhibitors of MYC-MAX interaction and function [J]. Oncogene, 2003, 22(40): 6151-6159.
[19]
HART J R, GARNER A L, YU J, et al. Inhibitor of MYC identified in a Krohnke pyridine library [J]. Proc Natl Acad Sci USA, 2014, 111(34): 12556-12561.
[20]
SINGH A, KUMAR A, KUMAR P, et al. A novel inhibitor L755507 efficiently blocks c-MYC-MAX heterodimerization and induces apoptosis in cancer cells [J]. J Biol Chem,2021, 297(1): 100903.
[21]
ZHANG C, LIU J, XU D D, et al. Gain-of-function mutant p53 in cancer progression and therapy [J]. J Mol Cell Biol,2020, 12(9): 674-687.
[22]
LIU J, ZHANG C, HU W W, et al. Tumor suppressor p53 and its mutants in cancer metabolism [J]. Cancer Lett,2015, 356(2 Pt A): 197-203.
[23]
VOUSDEN K H, LU X. Live or let die: the cell’s response to p53 [J]. Nat Rev Cancer, 2002, 2(8): 594-604.
[24]
DONEHOWER L A, HARVEY M, SLAGLE B L, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours [J]. Nature, 1992, 356(6366): 215-221.
[25]
ZAFAR A, WANG W, LIU G, et al. Targeting the p53-MDM2 pathway for neuroblastoma therapy: rays of hope[J]. Cancer Lett, 2021, 496: 16-29.
[26]
LUO X, O’NEILL K L, HUANG K. The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?[J]. F1000Res, 2020, 9: F1000 Faculty Rev-935.
[27]
EDLICH F. BCL-2 proteins and apoptosis: recent insights and unknowns [J]. Biochem Biophys Res Commun, 2018,500(1): 26-34.
[28]
DUFFY M J, O’GRADY S, TANG M H, et al. MYC as a target for cancer treatment [J]. Cancer Treat Rev, 2021, 94:102154.
[29]
YAMASHITA T, HIGASHI M, MOMOSE S, et al. Decreased MYC-associated factor X(MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma [J]. Sci Rep, 2020, 10(1): 10391.
[30]
LI Q, QUAN L, LYU J K, et al. Discovery of peptide inhibitors targeting human programmed death 1(PD-1) receptor [J]. Oncotarget, 2016, 7(40): 64967-64976.
[31]
CHEN T K, LI Q, LIU Z L, et al. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy? [J]. Eur J Med Chem, 2019,161: 378-398.
[32]
PAN C H, YANG H Y, LU Y, et al. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation [J]. Eur J Med Chem,2021, 213: 113170.
[33]
WU D D, GAO Y F, CHEN L X, et al. Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice [J]. Peptides, 2010, 31(5): 850-864.
[34]
GHASEMALI S, FARAJNIA S, BARZEGAR A, et al. Rational design of anti-angiogenic peptides to inhibit VEGF/VEGFR2 interactions for cancer therapeutics [J]. Anticancer Agents Med Chem, 2021, 22(10): 2026-2035.
[35]
WANG H F, SUN Y X, ZHOU X M, et al. CD47/SIRPalpha blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy [J]. J Immunother Cancer, 2020, 8(2): e000905.
[36]
HAZAMA D, YIN Y Z, MURATA Y, et al. Macrocyclic peptide-mediated blockade of the CD47-SIRP alpha interaction as a potential cancer immunotherapy [J]. Cell Chem Biol, 2020, 27(9): 1181-1191.
[37]
YI M, NIU M K, XU L P, et al. Regulation of PD-L1 expression in the tumor microenvironment [J]. J Hematol Oncol, 2021, 14(1): 10.
[38]
YANG J, HU L Q. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: from antibodies to small molecules [J]. Med Res Rev, 2019, 39(1): 265-301.
[39]
MARQUINA G, MANZANO A, CASADO A. Targeted agents in cervical cancer: beyond bevacizumab [J]. Curr Oncol Rep, 2018, 20(5): 40.
[40]
VEILLETTE A, CHEN J. SIRPα-CD47 immune checkpoint blockade in anticancer therapy [J]. Trends Immunol, 2018,39(3): 173-184.
[41]
LOGTENBERG M E W, SCHEEREN F A, SCHUMACHER T N. The CD47-SIRPα immune checkpoint [J]. Immunity,2020, 52(5): 742-752.
[42]
SHIN W H, KUMAZAWA K, IMAI K, et al. Current challenges and opportunities in designing protein-protein interaction targeted drugs [J]. Adv Appl Bioinform Chem,2020, 13: 11-25.
[43]
SCOTT D E, BAYLY A R, ABELL C, et al. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge [J]. Nat Rev Drug Discov,2016, 15(8): 533-550.
[44]
RAJAMANI K, THIRUGNANASAMBANDAN S S, NATESAN C, et al. Squalene deters drivers of RCC disease progression beyond VHL status [J]. Cell Biol Toxicol, 2021,37(4): 611-631.
[45]
XUE X, KANG J B, YANG X, et al. An efficient strategy for digging protein-protein interactions for rational drug design — a case study with HIF-1α/VHL [J]. Eur J Med Chem, 2022, 227: 113871.
[46]
BUCKLEY D L, VAN MOLLE I, GAREISS P C, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction [J]. J Am Chem Soc, 2012, 134(10): 4465-4468.
[47]
PELAY-GIMENO M, GLAS A, KOCH O, et al. Structure-based design of inhibitors of protein-protein interactions:mimicking peptide binding epitopes [J]. Angew Chem Int Ed Engl, 2015, 54(31): 8896-8927.
[48]
WANG Z, LI Z L, JI H T. Direct targeting of β-catenin in the wnt signaling pathway: current progress and perspectives[J]. Med Res Rev, 2021, 41(4): 2109-2129.
[49]
VAREKA M, DAHMS B, LANG M, et al. Synthesis of a Bcl9 alpha-helix mimetic for inhibition of PPIs by a combination of electrooxidative phenol coupling and Pd-catalyzed cross coupling [J]. Catalysts, 2020, 10(3): 340.
[50]
SONG J M, MENON A, MITCHELL D C, et al. High-throughput chemical probing of full-length protein-protein interactions [J]. ACS Comb Sci, 2017, 19(12): 763-769.
[51]
FASOLINI M, WU X Q, FLOCCO M, et al. Hot spots in Tcf4 for the interaction with beta-catenin [J]. J Biol Chem,2003, 278(23): 21092-21098.
[52]
BANCET A, RAINGEVAL C, LOMBERGET T, et al. Fragment linking strategies for structure-based drug design[J]. J Med Chem, 2020, 63(20): 11420-11435.
[53]
YAN F, LIU G M, CHEN T T, et al. Structure-based virtual screening and biological evaluation of peptide inhibitors for polo-box domain [J]. Molecules, 2019, 25(1): 107.
[54]
HAN Y, LIU W, CHEN L, et al. Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy [J]. Biomaterials,2021, 275: 120944.
[55]
YAN J, YAO Y, YAN S, et al. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction [J]. Nano Lett, 2020, 20(8): 5844-5852.
2023年第54卷第2期
21
7
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2023.02.003
  • 接收时间:2022-09-01
  • 首发时间:2026-11-19
  • 出版时间:2023-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-09-01
基金
作者信息
    南京医科大学药学院,江苏 南京 211166

通讯作者:

蒋南(1979—),女,副教授,从事计算机辅助药物设计和药物合成研究工作。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.02.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏